Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma

Summary

Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying the side effects and how well sunitinib malate works in treating patients with Kaposi sarcoma.

Timeline

Start

2009-01

Primary completion

2010-10

Completion

—

Outcome

Outcome not reported

Stopped (Enrollment): “No participants enrolled.”

Drugs

Indications